NHS

Showing 15 posts of 1107 posts found.

190509-f-jf989-059

NICE does not recommend cancer drug combination to the NHS

February 13, 2020
Business Services Cancer, Kidney cancer, NHS, NICE, keytruda, kidney disease

NICE has published draft guidance that does not recommend a new drug combination to combat untreated advanced renal cell carcinoma …

homeless-charity-poor-indifference

New report finds that health inequality in the UK greater than previously thought

February 12, 2020
Research and Development NHS, NICE, type 2 diabetes

Men are living seven years in poor health while women are living nearly ten years, according to a new report. …

five-clear-glass-vial-bottles

Scotland approves targetted combination therapy for advanced melanoma

February 11, 2020
Manufacturing and Production NHS, SMC, Scotland, UK, advanced melanoma, melanoma

The Scottish Medicines Consortium (SMC) has approved targeted combination therapy for the treatment of adult patient with unresectable or metastatic …

libtayo

Sanofi and Regeneron’s Libtayo approved on NHS Scotland for cutaneous squamous cell carcinoma

February 11, 2020
Manufacturing and Production, Sales and Marketing Libtayo, NHS, Regeneron, Sanofi, Scotland, nhs scotland, pharma

Scottish patients will now be able to access Sanofi and Regeneron’s Libtayo (cemiplimab) via the NHS after it became known …

NICE plans to use broader range of data in guidance

February 5, 2020
Research and Development NHS, NHS NICE, NICE

The British National Institute for Care Excellence has said it plans to use a broader range of data and analytics …

512px-gwyneth_paltrow_avp_iron_man_3_paris_2

NHS Chief Simon Stevens: Gwyneth Paltrow’s Goop poses “considerable risks to health”

January 31, 2020
Medical Communications Goop, Gwyneth Platrow, NHS, Simon Stevens, pharma

NHS Chief Executive Simon Stevens has gone head-to-head with Hollywood actor and “wellness guru” Gwyneth Paltrow, taking aim at her …

top_10_image_2

Top Ten most popular articles on Pharmafile.com this week

January 31, 2020
Medical Communications Janseen, Ketamine, NHS, NICE, Nasal sprays, Nasl, Top 10 of the week, top 10

This week nasal sprays based on illegal recreational drugs feature prominently, as the FDA has moved to approve Lannett Company’s …

pharmafocus_janfeb_2020_cover

Read the January/February 2020 edition of Pharmafocus online now!

January 30, 2020
Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing NHS, UK, US, brexit, coronavirus, opioid crisis, pharma

Pharmafocus returns for the New Year with its January/February issue, and things have certainly changed since we left. Brexit got …

janssen_latest_logo_on_sign

NICE rejects Janssen’s esketamine nasal spray Spravato for treatment-resistant depression

January 28, 2020
Manufacturing and Production, Sales and Marketing Janssen, NHS, NICE, Spravato, depression

Janssen’s Spravato (esketamine) nasal spray, derived from the party drug ketamine, has been turned down by NICE for NHS use …

NICE refuses Novo Nordisk’s obesity therapy Saxenda for NHS use

January 27, 2020
Sales and Marketing NHS, NICE, Novo Nordisk, UK, obesity, saxenda

NICE, the drug watchdog for England and Wales, has revealed that it has chosen not to recommend Novo Nordisk’s Saxenda …

woman-wearing-mouth-mask

UK tests 14 people for Chinese coronavirus

January 24, 2020
Medical Communications Chinese Coronavirus, NHS, Public Health England, Viral outbreaks, Viral pnemonia, coronavirus, epidemic

14 people in the UK have been tested for the Chinese coronavirus, according to Public Health England (PHE). In Scotland, …

NICE declines to recommend Astellas’ Xospata in rlapsed/refractory FLT3+ acute myeloid leukaemia

January 23, 2020
Sales and Marketing Astellas, NHS, NICE, UK, Xospata, acute myeloid leukaemia

The latest in a series of rejections over the past week, NICE has revealed that it has knocked back the …

Janssen’s ulcerative colitis medicine not recommended by NICE for use in adults

January 21, 2020
Manufacturing and Production IBS, Irrated Bowels, NHS, NICE, bowel, ulcerative colitis

NICE has published draft guidance which does not recommend Stelara (ustekinumab) for treating moderately to severely active ulcerative colitis in …

Novartis’ Mayzent granted license by the European Medicines Agency

January 21, 2020
Manufacturing and Production CNS, European Medicines Agency, NHS, NICE, Novartis

The European Medicines Agency (EMA) has granted a licence for the use of Mayzent (siponimod) in the treatment of certain …

lynparza

Lynparza tablets approved for NHS use in platinum-sensitive, BRCA-mutated ovarian, fallopian tube or peritoneal cancer

January 16, 2020
Sales and Marketing AstraZeneca, MSD, NHS, NICE, UK, lynparza

It has been announced that tablet form of Lynparza (olaparib), the PARP inhibitor developed by AstraZeneca and MSD, has secured …

The Gateway to Local Adoption Series

Latest content